VivoSeq
Psychiatry

Major Depressive Disorder

334

Pipeline Programs↗

79

Active Trials↗

104

Companies Involved↗

Major Depressive Disorder is a highly competitive landscape with 334 programs across 104 companies. The most active players are Astellas, Sumitomo Pharma America, Inc., Luye Pharma Group Ltd.. 89 therapies are approved with 78 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

89/100

Pipeline Velocity

53/100

Mech. Concentration

7/100

Completion Rate

86/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

2 programs

Phase 1Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.

1 program

Phase 1Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.

1 program

Phase 1S

Shenox Pharmaceuticals, LLC

1 program

Phase 1E

Engrail Therapeutics INC

1 program

Phase 1N

Nobilis Therapeutics Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical36

Botulinum Toxin Type a

Revance Therapeutics, Inc.

Nicotine

Pfizer

Ropinirole

Glaxo Dba Glaxosmithkline

Duloxetine Hydrochloride

Eli Lilly

Zinc Sulfate

Fakultas Kedokteran Universitas Indonesia

Phase 135

Zuranolone

Biogen

Paxil

Teva

Paroxetine CR

GSK

Memantine

AbbVie

Alcohol

Astellas

Phase 296

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Melatonin

Neurim Pharmaceuticals Ltd.

Ixekizumab

Eli Lilly

Dapagliflozin

AstraZeneca

Tasimelteon

Vanda Pharmaceuticals

Phase 378

Risperidone

Wim Janssens

Ketamine Hydrochloride

Boehringer Ingelheim

Midazolam

Conrado Roberto Hoffmann Filho

Quetiapine

Engelhard Arzneimittel GmbH & Co.KG

Aprepitant

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved89

Lorazepam

Bausch Health Americas, Inc.

Fremanezumab

Teva

Escitalopram

AbbVie

Valganciclovir

Engelhard Arzneimittel GmbH & Co.KG

Modafinil

Nuvo Research GmbH

Analysis

Modality Breakdown

98%

Small molecule

371 of 380 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody51%Peptide3<1%Vaccine1<1%

Small molecule leads; the ring shows all 380 classified programs, each share of the total. Modality classified for 99% of 387 pipeline programs.

Analysis

Trial Status

628

clinical trials

Completed434 · 69%
Terminated49 · 8%
Unknown status43 · 7%
Recruiting40 · 6%
Withdrawn20 · 3%
Active, not recruiting18 · 3%
Other24 · 4%

Clinical Trials

Trial Activity

628 trials

Neural Response to Inflammatory Challenge in Major Depressive Disorder
Recruiting·LLaureate Institute for Brain Research, Inc.·Phase 1/2·NCT04751331·180 enrolled
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Recruiting·—·Phase 3·NCT05973851·418 enrolled
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
Recruiting·AbbVie logoAbbVie·Phase 2·NCT07276997·195 enrolled
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Recruiting·VVanda Pharmaceuticals·Phase 3·NCT06830044·500 enrolled
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
Recruiting·Takeda logoTakeda·Phase 3·NCT07204314·180 enrolled
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
Recruiting·National Institute of Mental Health (NIMH)·Phase 1·NCT03065335·150 enrolled
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Recruiting·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 3·NCT06911112·200 enrolled
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
Recruiting·NNYU Langone Health·Phase 2·NCT05757791·16 enrolled
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Recruiting·SSirtsei Pharmaceuticals, Inc.·Phase 2·NCT06254612·456 enrolled
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
Recruiting·Supernus Pharmaceuticals, Inc. logoSupernus Pharmaceuticals, Inc.·Phase 2·NCT07226661·230 enrolled
Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting
Recruiting·TTheresa Jacob, PhD, MPH·Phase 3·NCT06752759·40 enrolled
NMDA Modulation in Major Depressive Disorder
Recruiting·—·Phase 2·NCT04637620·90 enrolled
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Recruiting·XXenon Pharmaceuticals Inc.·Phase 3·NCT06775379·450 enrolled
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Recruiting·XXenon Pharmaceuticals Inc.·Phase 3·NCT07076407·450 enrolled
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
Recruiting·—·Phase 2·NCT05136755·50 enrolled
Page 1 of 42

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)